In plain English
Merck & Co. develops and sells prescription medicines and vaccines, with a focus on oncology and immunology products such as Keytruda and…
Equity · NYSE · USD
MRK
Merck & Co Inc
$148.52
Today
−$1.81-1.20%
vs previous close
Quote
- Open
- $148.66
- High
- $149.60
- Low
- $146.28
- Prev close
- $150.33
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Size
- Large-cap
- Market cap
- $370.9B
- Shares out
- 2.47B
- Country
- US
- IPO
- Jan 1, 1941
- Exchange
- NYSE
- Website
- merck.com
Themes
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What MRK is
Plain English context — why the name shows up in the news, and what to watch next. Not a tip.
Latest on this name
Insights & deeper context
24 recent cards — open any for the full deeper dive.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
In brief
Positive Phase 3 results for a personalized mRNA cancer vaccine could ignite a new biotech boom beyond obesity drugs, boosting genomics and precision‑medicine ETFs.
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?
In brief
Measles deaths in Pennsylvania mark a worrying resurgence, with markets pricing a sharp rise in cases that could boost vaccine sales but strain public health efforts.
Moderna Stock Edges Higher Tuesday: What's Happening?
In brief
Moderna’s stock gains are driven by a breakthrough melanoma trial and analyst upgrades that boost its oncology outlook.
Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program
In brief
Merck’s challenge to the IRA’s drug‑price negotiation program was rejected, affirming federal pricing authority and exposing the company to lower prices or hefty penalties.
What’s Going On With Tempus AI Stock on Monday?
In brief
TEM’s recent pullback reflects a re‑pricing of its momentum‑driven rally, with FDA clearance adding a new product but analyst sentiment remaining split.
Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy
In brief
Oz’s statement counters Trump’s claim that MMR is lethal, but the new policy could still shift demand toward separate shots, impacting vaccine manufacturers.
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
In brief
Moderna’s Phase 3 cancer vaccine win has revived the stock, underscoring the company’s shift from pandemic focus to broader mRNA therapeutics.
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
In brief
Moderna’s Phase 3 melanoma win could be the catalyst that turns its mRNA platform into a sustainable oncology business, redefining its future beyond COVID‑19.
QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
In brief
Moderna’s record rally was quickly erased by a 25.69% slide, reflecting the high stakes of its first Phase 3 mRNA cancer therapy and the weight of its short‑interest profile.
Why Iovance Biotherapeutics Stock Hit 52-Week High
In brief
Iovance’s 52‑week high is fueled by industry momentum from Moderna and Merck’s breakthrough data, not by new company announcements, but by the broader confidence in individualized cancer therapies.
Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst
In brief
Intismeran’s strong interim data lift its approval odds and open a Keytruda‑style revenue stream, but investors remain cautious about its broader oncology potential.
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’
In brief
Moderna’s cancer‑vaccine win triggered a 177% stock jump that caught many traders off‑balance, exposing gaps in biotech positioning.
This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
In brief
Analyst upgrades across the board suggest a bullish tilt for PGR, MRK, EPR, ETSY, and ADI, with price targets climbing to $250, $179, $70, $105, and $425 respectively.
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)
In brief
Geopolitical tension over Iran and a likely Fed rate hike pushed markets lower, but economic data and sector moves keep volatility high.
Why Is Tempus AI Stock Gaining Thursday?
In brief
Positive melanoma trial results are lifting Tempus AI shares as investors weigh the strategic value of its planned Personalis acquisition.
Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
In brief
Analysts are broadly bullish, lifting price targets across tech and biotech, with Okta’s target jump to $170 indicating strong upside potential.
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
In brief
Positive Phase 3 cancer trial data for intismeran led to a sharp intraday rally in mRNA stocks, but after‑hours trading saw a pullback as investors took profits or reassessed upside.
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough
In brief
Moderna and Merck’s Phase 3 melanoma vaccine win validates mRNA oncology, sending shares soaring and boosting confidence in the platform’s future.
Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today
In brief
Moderna’s Phase‑3 win could pivot the company toward oncology, while Webull, Bitmine, Strategy, and Merck all benefited from strong earnings or market sentiment, driving significant intraday gains.
Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
In brief
The first positive Phase 3 mRNA cancer trial may revive the mRNA investment thesis beyond COVID and boost precision‑medicine ETFs.
Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made
In brief
Moderna’s Phase 3 win fuels a 100%+ stock rally, boosting President Trump’s blind‑trust holdings by up to $91k and underscoring the biotech sector’s growth prospects amid political scrutiny.
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions
In brief
Merck’s new commitment to mRNA cancer vaccines raises the stakes for Pfizer’s oncology ambitions, potentially reshaping the competitive dynamics of the mRNA‑oncology market.
Pfizer Stock Rises Wednesday: What's Going On?
In brief
Pfizer’s stock gains reflect growing confidence in mRNA cancer treatments after Merck and Moderna’s breakthrough melanoma trial.
Why Is BioNTech Stock Surging on Wednesday?
In brief
BioNTech’s stock surged after positive interim data and a 2026 late‑stage roadmap, lifting investor confidence in its mRNA cancer platform.
Filings & reports
SEC and filing-linked cards
No filings tagged yet
Filing-linked cards for MRK will show up here when available.
Indexes like the S&P 500 are shown via liquid ETFs (e.g. SPY). Company profile and quotes use live market data when available.